Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma
Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed to assess the efficacy of Betalutin (lilotomab), an innovative anti-CD37 antibody, in treating third-line (3L) follicular lymphoma patients who have previously failed anti-CD20 therapies. PARADIGME Trial Marks a Significant Milestone […]